Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Cash And Cash Equivalents At Carrying Value of $3.12 billion for the year ending 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +25.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: $135.38 million | Q2 2011: $254.31 million | Q3 2011: $206.40 million | Q1 2012: $394.59 million | Q2 2012: $171.94 million | Q3 2012: $119.00 million | Q1 2013: $180.36 million | Q2 2013: $381.68 million | Q3 2013: $263.21 million | Q1 2014: $461.86 million | Q2 2014: $600.14 million | Q3 2014: $646.55 million | Q1 2015: $507.91 million | Q2 2015: $390.55 million | Q3 2015: $654.59 million | Q1 2016: $604.21 million | Q2 2016: $646.51 million | Q3 2016: $920.36 million | Q1 2017: $811.77 million | Q2 2017: $744.31 million | Q3 2017: $792.07 million | Q1 2018: $1.02 billion | Q2 2018: $917.90 million | Q3 2018: $1.09 billion | Q1 2019: $1.71 billion | Q2 2019: $1.05 billion | Q3 2019: $1.38 billion | Q1 2020: $2.21 billion | Q2 2020: $1.99 billion | Q3 2020: $1.57 billion | Q1 2021: $1.44 billion | Q2 2021: $2.07 billion | Q3 2021: $3.43 billion | Q1 2022: $3.35 billion | Q2 2022: $3.40 billion | Q3 2022: $3.49 billion | Q1 2023: $3.92 billion | Q2 2023: $1.94 billion | Q3 2023: $2.15 billion | Q1 2024: $2.60 billion | Q2 2024: $1.92 billion | Q3 2024: $2.01 billion | Q1 2025: $3.09 billion | Q2 2025: $2.00 billion | Q3 2025: $2.51 billion.
- Over the full 16 years of available data (2010 to 2025), REGENERON PHARMACEUTICALS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 2,669.9%.
- Historical annual values: Fiscal year 2025: $3.12 billion | Fiscal year 2024: $2.49 billion | Fiscal year 2023: $2.73 billion | Fiscal year 2022: $3.11 billion | Fiscal year 2021: $2.89 billion | Fiscal year 2020: $2.19 billion | Fiscal year 2019: $1.62 billion | Fiscal year 2018: $1.47 billion | Fiscal year 2017: $812.70 million | Fiscal year 2016: $535.20 million | Fiscal year 2015: $809.10 million | Fiscal year 2014: $648.72 million | Fiscal year 2013: $535.61 million | Fiscal year 2012: $230.28 million | Fiscal year 2011: $483.61 million | Fiscal year 2010: $112.57 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: